[1] National Comprehensive Cancer Network.头颈部肿瘤临床实践指南(中国版,2010年第一版)[EB/OL]. [2014-09-01]. http://www.nccChina.org/nccn-guidelines-China.aspx.
[2] 王中和,涂文勇.口腔颌面-头颈肿瘤放射治疗学[M].上海:世界图书出版公司,2013:179-187.
[3] Bernier J, Bentzen SM, Vermorken JB. Molecular therapy in head and neck oncology[J]. Nat Rev Clin Oncol,2009,6(2):266-277.
[4] Chung TD, Broaddus WC. Molecular targeting in radiotherapy: epidermal growth factor receptor[J]. Molecular Interventions, 2005, 5(1):15-19.
[5] Dachs GU , Dougherty GY , Stratford IJ , et al . Targeting gene therapy to cancer: A review[J]. Oncol Res, 1997,9(2):313-325.
[6] Giovanni Melillo. Targeting hypoxia cell signaling for cancer therapy[J]. Cancer Metastasis Reviews, 2007, 26(2):341-352.
[7] Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for squamous cell carcinoma of the head and neck[J]. N Engl J Med, 2006,354(3):567-578.
[8] Huang SM, Harari PM. Modulation of radiation response after epidermal growth factor receptor blockade in squamous cell carcinomas: inhibition of damage repair, cell cycle kinetics, and tumor angiogenesis[J]. Clin Cancer Res, 2000,6(6):2166-2174.
[9] Kersemans V, Cornelissen B. Targeting the tumour: Cell penetrating peptides for molecular imaging and radiotherapy[J]. Pharmaceuticals, 2010, 3(3):600-620.
[10] Camphausen K, Tofilon PJ. Combining radiation and molecular targeting in cancer therapy[J]. Cancer biology therapy, 2004,3(3):247-250.
[11] Baumann M, Krause M. Targeting the epidermal growth factor receptor in radiotherapy: radiobiological mechanisms, preclinical and clinical results[J]. Radiother Oncol, 2004,72(3):257-266.
[12] 王中和.基因-放射治疗[J]. 中国现代临床医学杂志,2006,5(1):37-39.
[13] Kundu SK, Nestor M. Targeted therapy in head and neck cancer[J]. Tumor Biology, 2012, 33(3):707-721.
[14] Kasten-Pisula U, Saker J, Eicheler W, et al. Cellular tumor radiosensitivity is correlated to epidermal growth factor protein expression lever in tumors without EGFR amplification[J]. Int J Radiat Oncol Biol Phys, 2011,80(4):1181-1188.
[15] Thariat J, Milas LK, Ang K. Integrating radiotherapy with epidermal growth factor receptor antagonists and other molecular therapeutics for the treatment of head and neck cancer[J]. Int J Radiat Oncol Biol Phys, 2007,69(4):974-984.
[16] Garcia-Barros M, Paris F, Cordon-Cardo C, et al. Tumor response to radiotherapy regulated by endothelial cell apoptosis [J]. Science, 2003,300(5622):1155-1159.
[17] 王明国,王中和. mAb225与放射对舌鳞癌细胞凋亡的研究[J]. 口腔颌面外科杂志,2010,20(2):83-86.
[18] 王明国,王中和,胡海生. 表皮生长因子受体抗体对人舌鳞癌细胞增殖和放射敏感性的影响[J].中华放射肿瘤学杂志,2004,13(4):334.
[19] Siemann DW, Horsman MR.Vascular targeted therapies in oncology[J]. Cell Tissue Res, 2009, 335(1):241-248.
[20] Sundar SS, Ganesan TS. Role of lymphangiogenesis incancer[J]. J Clin Oncol, 2007, 25(27):4298-4307.
[21] Sugiura T, Inoue Y, Matsuki R,et al. VEGF-C and VEGF-D expression is correlated with lymphatic vessel density and lymph node metastasis in oral squamous cell carcinoma: Implications for use as a prognostic marker[J]. Int J Oncol,2009, 34(3):673-680.
[22] Siriwardena BS, Kudo Y, Ogawa I, et al. VEGF-C is associated with lymphatic status and invasion in oral cancer[J].J Clin Pathol, 2008, 61(1):103-108.
[23] Kuwahara Y, Mori M, Kitahara S, et al. Targeting of tumor endothelial cells combining 2 Gy/day of X-ray with Everolimus is the effective modality for overcoming clinically relevant radioresistant tumors.[J]. Cancer Medicine, 2014, 3(2): 310-321.
[24] Ansiaux R, Dewever J, Gregoire V, et al. Decrease in tumor cell oxygen consumption after treatment with vandetanib (ZACTIMA; ZD6474) and its effect on response to radiotherapy[J]. Radiat Res, 2009, 172(2):584-591.
[25] Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy[J]. Science, 2005, 307(5706):58-62.
[26] Seiwert TY, Haraf DJ, Cohen EE, et al. Phase I study of bevacizumab added to fluorouracil- and hydroxyurea-based concomitant chemoradiotherapy for poor-prognosis head and neck cancer[J]. J Clin Oncol, 2008, 26(10):1732-1741.
[27] Noeden AD, Drappatz J, Wen PY, et al. Novel anti-angiogenic therapies for malignant gliomas[J]. Lancet Neurol, 2008, 7(12):1152-1160.
[28] Huber PE, Bischof M, Jenne J,et al. Trimodal cancer treatment: Beneficial effects of combined antiangiogenesis radiation, and chemotherapy[J]. Cancer Res, 2005, 65(9):3643-3655.
[29] Wachsberger P, Burd R, Dicker AP. Tumor response to ionizing radiation combined with antiangiogenesis or vascular targeting agents: exploring mechanisms of interaction[J]. Clin Cancer Res, 2003, 9(6):1957-1071.
[30] Balermpas P, Hambek M, Seitz O, et al. Combined cetuximab and reirradiation for locoregional recurrent and inoperable squamous cell carcinoma of the head and neck[J].Strahlenther Onkol, 2009, 185(12):775-781.
[31] Heron DE, Rwigema JC, Gibson MK, et al. Concurrent cetuximab with stereotactic radiotherapy for recurrent squamous cell carcinoma of the head and neck: A single institution matched case-control study[J]. Am J Oncol, 2011, 34(2):165-172.
[32] Comet B, Kramar A, Faivre-Pierret M, et al. Salvage stereotactic reirradiation with or without cetuximab for local recurrent head-and-neck cancer: A feasibility study[J]. Int J Radiat Oncol Biol Phys, 2012, 84(1):203-209.
[33] Studer G, Brown M, Salgueiro EB, et al. Grade 3/4 dermatitis in head and neck cancer Patients treated With concurrent Cetuximab and IMRT[J]. Int J Radiat Oncol Biol Phys, 2010, 81(1):110-117.
[34] Cohen EE,Haraf DJ,Kunnavakkam R. et al. Epidermal growth factor receptor inhibitor gefitinib added to chemoradiotherapy in locally advanced head and neck cancer[J]. J Clin Oncol, 2010, 28(20):3336-3343.
[35] Herchenhorn D, Diasn FL, Viegas C, et al. Phase I/II study of Erlotinib combined with cisplatin and radiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck[J]. Int J Radiat Oncol Biol Phys, 2010, 78(3):696-702.
[36] Vermorken JB, Mesia R, Rivera F, et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer[J]. N Engl J Med, 2008, 359(11):1116-1127.
[37] Burtness B, Goldwasser MA, Flood W, et al. Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent Head and neck cancer: an Eastern Cooperative Oncology group study[J]. J Clin Oncol, 2005, 23(34): 8646-8654.
[38] Bozec A, Sudaka A, Fischel JL, et al. Combined effects of bevacizumab with erlotinib and irradiation: a preclinical study on a head and neck cancer orthotopic model[J].Br J Cancer, 2008, 99(1):93-99.
[39] Koontz BF, Miles EF, Rubio MA, et al. Preoperative radiotherapy and bevacizumab for angiosarcoma of the head and neck: two case studies[J]. Head Neck, 2008,30(2):262-266.
[40] Setton J, Caria N, Romanyshyn J, et al. Intensity-modulated radiotherapy in the treatment of oropharyngeal cancer: an update of the Memorial Sloan-Kettering Cancer Center experience[J]. Int J Radiat Oncol Biol Phys, 2012, 82(1):291-298.
[41] Hayden EC. Personalized cancer therapy gets closer[J]. Nature, 2009, 458 (7235):131-132.
[42] Ding M, Erlong Zhang E, He R, et al. Newly developed strategies for improving sensitivity to radiation by targeting signal pathways in cancer therapy[J]. Cancer Science, 2013,104(11):1401-1410. |